1. Effect of magnesium level before allogeneic hematopoietic cell transplantation on outcome in acute leukemia.
- Author
-
Fan Q, Hui X, Zhang Y, and Wang Y
- Subjects
- Humans, Female, Male, Adult, Middle Aged, Adolescent, Prognosis, Young Adult, Acute Disease, Treatment Outcome, Leukemia, Myeloid, Acute therapy, Leukemia, Myeloid, Acute mortality, Cyclosporine therapeutic use, Leukemia therapy, Leukemia mortality, Hematopoietic Stem Cell Transplantation, Magnesium blood, Graft vs Host Disease, Transplantation, Homologous
- Abstract
This study assessed the effect of serum magnesium levels and their role in the outcome of allogeneic hematopoietic cell transplantation (allo-HSCT) in acute leukemia. Fifty-four patients with acute leukemia who underwent allo-HSCT were divided into two groups according to their serum magnesium levels before transplantation. The results showed that serum magnesium level is an independent factor influencing the prognosis of patients undergoing allo-HSCT. Low magnesium levels were associated with inferior overall survival and event-free survival compared with the associations of high magnesium levels (HR = 0.149; (95% CI: 0.029-0.755 for overall survival; HR = 0.369; 95% CI: 0.144-0.949, p = 0.039 for event-free survival). The competing risk model showed that the cumulative incidence of acute graft-versus-host disease was significantly low in the high magnesium group (p = 0.028). In general, there is a correlation between high magnesium levels and superior outcomes, including less and milder acute graft-versus-host disease, which does not affect cyclosporine-A levels. These findings provide valuable information for identifying the risk of poor prognosis in patients preparing for transplantation., Competing Interests: Declaration of competing interest The authors declare that they have no conflict of interest., (Copyright © 2024 Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF